2,4,6-Trimethyl-5,7-dihydropyrrolo[3,4-d]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 2,4,6-Trimethyl-5,7-dihydropyrrolo[3,4-d]pyrimidine
• 英文别名: 2,4,6-trimethyl-5,7-dihydropyrrolo[3,4-d]pyrimidine
• 化学式: C₉H₁₃N₃
• 分子量: 163.22
• InChiKey: BPGJPLQQMXFZDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2018066718A1

  公开（公告）日：2018-04-12

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : in which n, X, R1, R2, R3 and R4 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式(I)的化合物及其药用盐：其中n、X、R1、R2、R3和R4如规范中定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
  申请人：Lynch Rosemary

  公开号：US20140163023A1

  公开（公告）日：2014-06-12

  The invention relates to compounds of formula (I) wherein X, R 1 , R 2 , T 0 , o have the meaning as cited in the description and the claims. The compounds of formula I are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds of formula I, the preparation of such compounds as well as the use as medicaments.

  本发明涉及公式(I)的化合物，其中X，R1，R2，T0，o的含义如描述和权利要求中所述。公式I的化合物可用作mTOR的抑制剂，用于治疗或预防与mTOR相关的疾病和紊乱。本发明还涉及包括公式I的化合物的制药组合物，以及作为药物使用的制备方法。
• RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF
  申请人：Beijing Tide Pharmaceutical Co., Ltd.

  公开号：EP3647311A1

  公开（公告）日：2020-05-06

  The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).

  本发明涉及一种式（I）的Rho相关蛋白激酶抑制剂、一种包含其的药物组合物、其制备方法以及其在预防或治疗由Rho相关蛋白激酶（ROCK）介导的疾病中的用途。
• METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS
  申请人：Beijing Tide Pharmaceutical Co., Ltd.

  公开号：EP3932404A1

  公开（公告）日：2022-01-05

  The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.

  本发明属于生物医学领域，具体涉及一种预防、减轻和/或治疗脂肪肝和/或脂肪性肝炎的方法。该方法包括向有需要的个体施用有效量的式（I）化合物或其药学上可接受的盐、酯、立体异构体、多晶型、溶解物、N-氧化物、同位素标记的化合物、代谢物或原药。
• [EN] RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF<br/>[FR] INHIBITEUR DE PROTÉINE KINASE ASSOCIÉE À RHO, COMPOSITION PHARMACEUTIQUE LE COMPRENANT, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
  申请人：BEIJING TIDE PHARMACEUTICAL CO LTD

  公开号：WO2019001572A1

  公开（公告）日：2019-01-03

  本发明涉及式 (I) 的Rho相关蛋白激酶抑制剂、包含其的药物组合物、其制备方法及其用于预防或治疗Rho相关蛋白激酶（ROCK）介导的疾病的用途。(I)